. Formation of study population suggest that double-unit CB grafts may be associated with a protection against relapse. However, given there are no randomized trials comparing survival after URD-T and DCB-T, this question is a subject of ongoing controversy. Methods: We evaluated 211 consecutive adult allograft recipients (153 URD-T and 58 DCB-T) aged 16-60 years transplanted 10/2005-12/2012 for acute leukemia in morphologic remission (115 AML/ biphenotypic, 52 ALL), MDS with 5% bone marrow blasts at work-up (n ¼ 32), or advanced CML (n ¼ 12). URD were 8-10/10 HLA-matched (89 10/10, 52 9/10, 12 8/10). CB grafts were 4-6/6 donorrecipient HLA-matched (6 6/6, 53 5/6, 57 4/6). All patients received either myeloablative or reduced intensity conditioning. GVHD prophylaxis was calcineurin-inhibitor/MMF based in DCB-T recipients whereas the majority of URD-T recipients (n ¼ 138, 90%) received T-cell depleted (TCD) grafts.
Results: The median ages of URD-T (46 years) and DCB-T (42 years) recipients were similar (p ¼ 0.22) and distribution of diagnoses was also similar. Neutrophil engraftment was inferior in DCB-T (95%, median 24 days) as compared to URD-T (100%, median 11 days) recipients (p <0.001), and GVHD rates were significantly higher in DCB-T as compared to TCD URD-T recipients (data not shown). Survival end-points are shown in the Table. The median (range) follow-up of survivors are similar in URD-T (46 months, 9-96) and DCB-T (42 months, 11-88) groups. While the 6-month transplant-related mortality (TRM) was higher in DCB-T (21%) versus URD-T (8%) recipients, the 3-year TRM were similar (p ¼ 0.860). Moreover, the 3-year relapse risk was significantly decreased in DCB-T recipients (7%, p ¼ 0.009). DCB-T recipients had a 70% 3-year DFS (p ¼ 0.08, Figure) . Conclusions: These results provide highly encouraging preliminary data. In the absence of a large randomized trial in adult patients which will be extremely challenging to conduct in the U.S., further investigation of larger patient populations controlled for possible confounding factors is needed. However, in the interim, this data supports DCB-T (performed in centers with a strong interest in the optimal conduct of CB-T) as an immediate alternative to URD-T given the strong protection against relapse in patients with acute leukemia and other high-risk myeloid malignancies such as CML and MDS. (Figure) . We then analyzed the components of infused viable CD34+ cell dose (i.e. postthaw CD34+ cell count and percent viability) in 402 units (302 domestic and 100 international) from 43 Banks thawed at our TC. Bank CD34+ cell count correlated with post-thaw measurements (r 2 ¼ 0.6, p < 0.001). The median CD34+ cell recovery was 101% but ranged 12-1480%. Recovery < 65% occurred less frequently in units from FACT-accredited Banks. Moreover, while the median post-thaw CD34+ cell viability was 92%, 33 (8%) units had < 75% viable CD34+ cells post-thaw. Bank FACT accreditation and CB unit cryovolume were significantly associated with post-thaw viability (Table) . Bank location (all domestic vs. all international), shipping distance (local vs. distant international) and duration of cryopreservation were not associated with viability. Conclusion: Infused viable CD34+ cell dose was the critical determinant of engraftment, and CD34+ cell count recovery and viability were linked to differences in banking practices. These findings have significant implications for banking and CB unit selection. At our TC, we now prioritize standard 25ml units from FACT-accredited banks and strongly consider the CD34+ cell dose. However, with such a practice, TC must be able to react to lower than expected post-thaw CD34+ cell counts and/or low CD34+ cell viability. This requires measurement of the infused viable CD34+ cell dose (or another rapidly available measure of potency) on transplant day and a back-up strategy in case of a compromised unit. This is even more critical in single-unit CBT in which engraftment is solely dependent on a single unit. 
